CN1289098C - 溶瘤病毒 - Google Patents

溶瘤病毒 Download PDF

Info

Publication number
CN1289098C
CN1289098C CNB008158983A CN00815898A CN1289098C CN 1289098 C CN1289098 C CN 1289098C CN B008158983 A CNB008158983 A CN B008158983A CN 00815898 A CN00815898 A CN 00815898A CN 1289098 C CN1289098 C CN 1289098C
Authority
CN
China
Prior art keywords
vsv
virus
cells
sequence
pkr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008158983A
Other languages
English (en)
Chinese (zh)
Other versions
CN1496268A (zh
Inventor
J·C·贝尔
N·索宁贝格
D·F·斯托德尔
E·G·布朗
H·L·阿特金斯
R·M·马里乌斯
B·D·利克蒂
S·B·诺勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIRUSTA BIOLOGICAL Inc
Original Assignee
VIRUSTA BIOLOGICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIRUSTA BIOLOGICAL Inc filed Critical VIRUSTA BIOLOGICAL Inc
Publication of CN1496268A publication Critical patent/CN1496268A/zh
Application granted granted Critical
Publication of CN1289098C publication Critical patent/CN1289098C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CNB008158983A 1999-09-17 2000-09-18 溶瘤病毒 Expired - Fee Related CN1289098C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
US09/397,873 1999-09-17

Publications (2)

Publication Number Publication Date
CN1496268A CN1496268A (zh) 2004-05-12
CN1289098C true CN1289098C (zh) 2006-12-13

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008158983A Expired - Fee Related CN1289098C (zh) 1999-09-17 2000-09-18 溶瘤病毒

Country Status (13)

Country Link
EP (2) EP1218019B1 (https=)
JP (1) JP5060694B2 (https=)
CN (1) CN1289098C (https=)
AT (2) ATE319460T1 (https=)
AU (1) AU782402B2 (https=)
CA (1) CA2386920C (https=)
DE (2) DE60041210D1 (https=)
ES (2) ES2320239T3 (https=)
HK (1) HK1044708B (https=)
IL (2) IL148621A0 (https=)
MX (1) MXPA02002772A (https=)
NZ (4) NZ517573A (https=)
WO (1) WO2001019380A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
CA2412493C (en) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
JP2007524363A (ja) 2003-03-27 2007-08-30 オタワ ヘルス リサーチ インスティチュート 変異体水疱性口内炎ウイルスおよびそれらの使用
US8012747B2 (en) 2004-06-01 2011-09-06 San Diego State University Foundation Expression system
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
RU2010124788A (ru) * 2007-12-21 2012-01-27 Ваейт ЭлЭлСи (US) Генетически модифицированный ослабленный вирус везикулярного стоматита, композиции и способы их применения
EP2349296B1 (en) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US9707285B2 (en) 2009-03-16 2017-07-18 Turnstone Limited Partnership Vaccination methods
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012031137A2 (en) 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
PL2983706T3 (pl) * 2013-04-10 2021-11-02 Isd Immunotech Aps Zastosowanie domen tłumiących układ immunologiczny jako leków
WO2014198003A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions and methods for enhancing virus replication
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
WO2016013008A1 (en) * 2014-07-21 2016-01-28 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
EP3624825A4 (en) 2017-05-19 2021-03-10 Georgia State University Research Foundation, Inc. RECOMBINANT ONCOLYTIC VIRUS
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
JP7799945B2 (ja) * 2017-09-22 2026-01-16 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
WO2022033469A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
AU673827B2 (en) * 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
DE69837764T2 (de) * 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
CN101618049A (zh) * 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
JP4544497B2 (ja) * 1997-12-22 2010-09-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 異種融合タンパク質を有する組変えラブドウイルス
EP1061806A4 (en) * 1998-03-12 2001-09-12 Univ Pennsylvania REPLICATING VIRUS PRODUCING CELLS FOR TREATING MALIGNANCY
JP4837827B2 (ja) * 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses

Also Published As

Publication number Publication date
DE60026554D1 (de) 2006-05-04
DE60041210D1 (de) 2009-02-05
ES2320239T3 (es) 2009-05-20
EP1218019A2 (en) 2002-07-03
HK1092713A1 (en) 2007-02-16
WO2001019380A2 (en) 2001-03-22
AU782402B2 (en) 2005-07-28
EP1716858A2 (en) 2006-11-02
NZ517573A (en) 2004-02-27
ES2260057T3 (es) 2006-11-01
EP1716858B9 (en) 2009-08-12
WO2001019380A3 (en) 2001-11-22
JP5060694B2 (ja) 2012-10-31
CA2386920C (en) 2012-01-24
CN1496268A (zh) 2004-05-12
HK1044708B (en) 2006-10-27
AU7588200A (en) 2001-04-17
JP2004525855A (ja) 2004-08-26
NZ534306A (en) 2005-12-23
IL148621A (en) 2010-02-17
EP1218019B1 (en) 2006-03-08
MXPA02002772A (es) 2004-04-02
HK1044708A1 (en) 2002-11-01
NZ534307A (en) 2005-07-29
CA2386920A1 (en) 2001-03-22
IL148621A0 (en) 2002-09-12
DE60026554T2 (de) 2006-09-28
EP1716858A3 (en) 2007-08-15
ATE418341T1 (de) 2009-01-15
NZ523805A (en) 2004-09-24
EP1716858B1 (en) 2008-12-24
ATE319460T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
CN1289098C (zh) 溶瘤病毒
US8147822B1 (en) Oncolytic virus
CN1820078A (zh) 弹状病毒的重组突变体及其应用方法
CN1788088A (zh) 突变的水泡性口炎病毒及其用途
CN1118569C (zh) 具有自主复制能力的负链rna病毒载体
CN1477964A (zh) 应用病毒治疗肿瘤
Watanabe et al. Measles virus mutants possessing the fusion protein with enhanced fusion activity spread effectively in neuronal cells, but not in other cells, without causing strong cytopathology
CN1281336A (zh) 使用病毒来治疗赘生物
CN1122105C (zh) 新的突变病毒、抗病毒化合物和新的制备疫苗的方法
CN101056646A (zh) 重组新城疫病毒
Durbin et al. PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent
CN100346826C (zh) 通过核蛋白在磷酸化位点突变的减弱狂犬病病毒用于抗狂犬病的接种以及在cns中的基因治疗
CN1426462A (zh) 抗干扰素(ifn)反应的肺炎病毒非结构蛋白
HK1095608A (en) Recombinatant mutants of rhabdovirus and methods of use thereof
Gaddy Analysis of host gene products that contribute to the induction of apoptosis by oncolytic vesicular stomatitis virus
Walton Activation and Subversion of MDA5-Dependent Immune Responses by the Engineered Oncolytic Poliovirus PVSRIPO
Usai Characterization of a mouse model for the study of hepatitis delta virus infection
Hasenkrug Temporal Effects of Gamma Interferon Deficiency on the Course of Friend Retrovirus Infection in Mice
HK1087329A (en) Dc-sign blockers and their use for preventing or treating viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213

Termination date: 20130918